Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CryositeASX:CTE 70 10-Year Share Buyback Ratio is -0.60 as of Jun. 2026. GuruFocus rates ASX:CTE with a GF Score™ of 70/100 and a GF Value™ of A$1.02 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 134 Medical Diagnostics & Research companies, Cryosite ranks better than 76.12% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Cryosite's current 10-Year Share Buyback Ratio was -0.60%.
ASX:CTE's 10-Year Share Buyback Ratio is ranked better than 76.12% of 134
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.45
vs ASX:CTE: -0.60
Cryosite (ASX:CTE) 10-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Cryosite 10-Year Share Buyback Ratio Related Terms
ASX:CTE vs TMO, DHR, NTRA: 10-Year Share Buyback Ratio Comparison
For the Diagnostics & Research subindustry, Cryosite's 10-Year Share Buyback Ratio, along with its competitors' market caps and 10-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryosite 10-Year Share Buyback Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cryosite's 10-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Cryosite's 10-Year Share Buyback Ratio falls into.
This is the annualized percentage change in shares outstanding from ten years ago to the current year. The annualized percentage change is calculated with least-square regression based on the eleven years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 10-Year Share Buyback Ratio of -0.60 mean?
Cryosite (ASX:CTE) has a 10-Year Share Buyback Ratio of -0.60 as of Jun. 2026. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Cryosite and its competitors. According to the industry distribution chart, Cryosite ranks #32 out of 134 companies in the Medical Diagnostics & Research industry, placing it in the top 23.9%.
Is Cryosite's 10-Year Share Buyback Ratio too high?
Cryosite's current 10-Year Share Buyback Ratio is -0.60. Based on the distribution chart, Cryosite ranks #32 out of 134 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Cryosite has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cryosite's 10-Year Share Buyback Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cryosite ranks #32 out of 134 companies for 10-Year Share Buyback Ratio. This places Cryosite in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year Share Buyback Ratio for a Medical Diagnostics & Research company?
A good 10-Year Share Buyback Ratio depends on the Medical Diagnostics & Research industry context. However, 10-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year Share Buyback Ratio mean?
A high 10-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Cryosite and its competitors. Cryosite's current 10-Year Share Buyback Ratio is -0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryosite stock overvalued right now?
Based on GuruFocus' analysis, Cryosite (ASX:CTE) is currently considered Modestly Overvalued. The stock's GF Value™ is A$1.02, compared to a current price of A$1.25 — trading 22.5% above its estimated fair value. The current 10-Year Share Buyback Ratio is -0.60. Cryosite's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year Share Buyback Ratio calculated?
10-Year Share Buyback Ratio is calculated from a company's financial statements. For Cryosite (ASX:CTE), the current 10-Year Share Buyback Ratio is -0.60 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryosite (ASX:CTE) Overvalued in 2026?
Based on GuruFocus' analysis, Cryosite stock appears to be overvalued.
The current stock price of A$1.25 is trading 22.5% above its estimated GF Value™ of A$1.02.
GuruFocus considers Cryosite to be Modestly Overvalued.
Key valuation signals for ASX:CTE:
10-Year Share Buyback Ratio: -0.60
GF Value™: A$1.02 vs. price of A$1.25 (22.5% above fair value)
No single metric tells the full story. See the ASX:CTE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryosite Ltd provides an integrated clinical trial logistics service, biological storage and sample management service, including the storage of cord blood stem cells for private use. It supports a diverse portfolio of materials, including Good Manufacturing Practice (GMP) clinical trial products, Australian Register of Therapeutic Goods (ARTG) approved medicines, biologics, Research and Development materials, and medical devices, among others. The group's operating segments are: Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord blood. The majority of its revenue is generated from the Ambient, cold, and frozen segment, which provides storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions.
70GF Score
Get the complete analysis for ASX:CTE
10-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CTE has been successfully added to your 
